Research Article| Volume 19, ISSUE 3, P527-536, May 1997

Effect of doxazosin therapy on glucose tolerance and lipid metabolism in hypertensive patients with impaired glucose tolerance

      This paper is only available as a PDF. To read, Please Download here.


      The effects of long-term monotherapy with doxazosin, an alpha1-blocker, or placebo on blood pressure (BP), glucose tolerance, and serum lipid levels were investigated prospectively in 43 hypertensive patients with impaired glucose tolerance. The levels of plasma glucose, serum lipids, fructosamine, and glycated hemoglobin A1c (Hb A1c) were determined before and during long-term (mean treatment period, 6.7 months) therapy with doxazosin (n = 23) or placebo (n = 20). A 75-g oral glucose tolerance test was performed before and during therapy. Significant decreases in both systolic and diastolic BP were maintained during doxazosin therapy; BP did not change in the placebo group. Neither fasting nor post—glucose-load venous plasma glucose levels were altered, and there was no significant change in the insulinogenic index in either group. Glucose intolerance was slightly improved with significant reductions in Hb A1c and fructosamine levels during doxazosin therapy. Serum total cholesterol (TC) and low-density lipoprotein (LDL) cholesterol levels were significantly decreased, and high-density lipoprotein cholesterol levels were significantly increased in patients treated with doxazosin. Moreover, TC, LDL cholesterol, and apolipoprotein B levels were significantly decreased in patients with hypercholesterolemia (TC ≥5.69 mmol/L). In contrast, there were no significant changes in Hb A1c, fructosamine, and lipid levels in the placebo group. These results suggest that long-term doxazosin therapy may improve glucose and lipid metabolism in hypertensive patients. Doxazosin appears useful as an antihypertensive agent for hypertensive patients with either impaired glucose metabolism or dyslipidemia.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kolata G
        Heart study produces surprise results.
        Science. 1982; 218: 31-32
        • Multiple Risk Factor Intervention Trial Research Group
        Multiple risk factor intervention trial, risk factor changes and mortality results.
        JAMA. 1982; 248: 1465-1477
        • Struthers AD
        • Murphy MB
        • Dollery CT
        Glucose tolerance during antihypertensive therapy in patients with diabetes mellitus.
        Hypertension. 1985; 7 (Suppl II): 95-101
        • Ferrannini E
        • Buzzigoli G
        • Bonadonna R
        • et al.
        Insulin resistance in essential hypertension.
        NEJM. 1987; 317: 350-357
        • Shionoiri H
        • Noda K
        • Miyamoto K
        • et al.
        Glucose tolerance during chronic prazosin therapy in patients with essential hypertension.
        Curr Ther Res. 1986; 40: 171-180
        • Shionoiri H
        • Miyakawa T
        • Takasaki I
        • et al.
        Glucose tolerance during chronic captopril therapy in patients with essential hypertension.
        J Cardiovasc Pharmacol. 1987; 9: 160-164
        • Pollare T
        • Lithell H
        • Selinus I
        • Berne C
        Sensitivity to insulin during treatment with atenolol and metaprolol: A randomized, double-blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.
        BMJ. 1989; 298: 1152-1157
        • Berne C
        • Pollare T
        • Lithell H
        Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors.
        Diabetes Care. 1991; 14 (Suppl 4): 39-47
        • Shionoiri H
        • Sugimoto K
        • Minamisawa K
        • long-term treatment with cilazapril in
        • hypertensive patients with or without impaired
        • glucose metabolism
        • et al.
        J Cardiovasc Pharmacol. 1990; 15: 933-938
        • Shionoiri H
        • Ueda S
        • Gotoh E
        • et al.
        Glucose and lipid metabolism during long-term lisinopril therapy in hypertensive patients.
        J Cardiovasc Pharmacol. 1990; 16: 905-909
        • Shionoiri H
        • Gotoh E
        • Ito T
        • et al.
        Long-term therapy with terazosin may improve glucose and lipid metabolism in hypertensives: A multicenter prospective study.
        Am J Med Sci. 1994; 307 (Suppl 1): S91-S95
        • Shionoiri H
        • Takasaki I
        • Naruse M
        • et al.
        Effect of cilazapril therapy on glucose and lipid metabolism in patients with hypertension.
        Clin Ther. 1995; 17: 1126-1135
        • Feher MD
        • Henderson AD
        • Wadsworth J
        • et al.
        Alpha-blocker therapy: A possible advance in the treatment of diabetic hypertension. Results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects.
        J Hum Hypertens. 1990; 4: 571-577
        • Lehtonen A
        Doxazosin effects on insulin and glucose in hypertensive patients.
        Am Heart J. 1991; 121 (The Finnish Multicenter Study Group): 1307-1311
      1. Diabetes Mellitus: Report of a WHO Study Group. World Health Organization, Geneva1985 (Technical report series, No. 727)
        • Castelli WP
        Cardiovascular disease and multifactorial risk: Challenge of the 1980s.
        Am Heart J. 1983; 106: 1191-1200
        • Doruhorst A
        • Powell S
        • Pensky J
        Aggravation by propranolol of hyperglycemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.
        Lancet. 1985; 1: 123-126
        • Abbott RD
        • Wilson PWF
        • Kannel WB
        • Castelli WP
        High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham study.
        Arteriosclerosis. 1988; 8: 207-211
        • Manninen V
        • Elo MO
        • Frick MH
        • et al.
        Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki study.
        JAMA. 1988; 260: 641-651
        • Ferra LA
        • Marotta T
        • Rubba P
        • et al.
        Effects of alpha-adrenergic and beta-adrenergic receptor blockade on lipid metabolism.
        Am J Med. 1986; 80 (Suppl 5B): 104-108
        • Lytle TB
        • Coles SJ
        • Waite MA
        A multi-center, hospital study of the efficacy and safety of terazosin and its effects on the plasma cholesterol levels of patients with essential hypertension.
        J Clin Pharm Ther. 1991; 16: 263-273
        • Deger G
        Effect of terazosin on serum lipids.
        Am J Med. 1986; 80 (Suppl 5B): 82-85
        • Krupp MN
        • Hoover KW
        • Valentine JJ
        Effects of doxazosin and other antihypertensives on serum lipid levels and lipoprotein lipase in the C57BR/cdJ mouse.
        J Cardiovasc Pharmacol. 1989; 13 (Suppl 2): S11-S19
        • Jansen H
        • Lammers R
        • Baggen MGA
        • Birkenhåger JC
        Effects of doxazosin on lipids, lipoprotein lipase, and cholesterol synthesis in the golden hamster.
        J Cardiovasc Pharmacol. 1989; 13 (Suppl 2): S5-S10
        • D'Eletto RD
        • Javitt NB
        Effect of doxazosin on cholesterol synthesis in cell culture.
        J Cardiovasc Pharmacol. 1989; 13 (Suppl 2): S1-S4
        • The Fifth Report of the Joint National Committee on Detection
        Evaluation, and Treatment of High Blood Pressure (JNC V).
        Arch Intern Med. 1993; 153: 154-183
      2. National High Blood Pressure Education Program Working Group report on hypertension in diabetes.
        Hypertension. 1994; 23: 145-158